N-cyclopropyl-stearoyl amide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-cyclopropyl-stearoyl amide
• 英文别名: N-cyclopropyloctadecanamide
• 化学式: C₂₁H₄₁NO
• 分子量: 323.563
• InChiKey: QSYJXLFKTLRZHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.5
• 重原子数：
  23
• 可旋转键数：
  17
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  硬脂酸 、 环丙胺 以0.86%的产率得到N-cyclopropyl-stearoyl amide
  参考文献：
  名称：

  USE OF ENDOCANNABINOID-LIKE COMPOUNDS FOR TREATING CNS DEGENERATIVE DISORDERS

  摘要：

  公开号：

  EP1592418B1

文献信息

• New endocannabinoid-like compounds and their use
  申请人：RESEARCH & INNOVATION SOC. COOP. A R.L.

  公开号：EP1900365A2

  公开（公告）日：2008-03-19

  The present invention describes compounds deriving from chemical reactions between saturated or monounsaturated acyl derivatives and primary amines or primary alcohols that display specific cannabinoid-like pharmacological activity without exhibiting the central unwanted side effects typical of synthetic cannabinoids or endocannabinoids acting on central cannabinoid (CB1) receptors. These compounds, having this pharmacological activity, may be utilised to prevent or to treat pathological conditions and diseases in mammals, including human subjects, that may undergo a clinical improvement upon their administration.

  本发明描述了由饱和或单不饱和酰基衍生物与伯胺或伯醇之间的化学反应所产生 的化合物，这些化合物显示出类似大麻素的特殊药理活性，而不会表现出合成大麻 素或作用于中枢大麻素（CB1）受体的内源性大麻素所特有的中枢性不良副作用。这些具有这种药理活性的化合物可用于预防或治疗哺乳动物（包括人类）的病理状况和疾病，服用后可改善临床症状。
• USE IN THERAPY OF ENDOCANNABINOID-LIKE COMPOUNDS
  申请人：Research & Innovation Soc. Coop. A R.L.

  公开号：EP1592418A2

  公开（公告）日：2005-11-09
• Endocannabinoid-like compounds and their use for treating dermatitis
  申请人：Research & Innovation S.p.A.

  公开号：EP1900365B1

  公开（公告）日：2011-03-30
• [EN] NEW ENDOCANNABINOID-LIKE COMPOUNDS AND THEIR USE<br/>[FR] NOUVEAUX COMPOSES DE TYPE ENDOCANNABINOIDE ET LEUR UTILISATION
  申请人：RES & INNOVATION SOC COOP A R

  公开号：WO2004069240A2

  公开（公告）日：2004-08-19

  The present invention describes compounds deriving from chemical reactions between saturated or monounsaturated acyl derivatives and primary alcohols that display specific cannabinoid-like pharmacological activity without exhibiting the central unwanted side effects typical of synthetic cannabinoids or endocannabinoids acting on central cannabinoid (CB1) receptors. These compounds, having this pharmacological activity, may be utilised to prevent or to treat pathological conditions and diseases in mammals, including human subjects, that may undergo a clinical improvement upon their administration.
• USE OF ENDOCANNABINOID-LIKE COMPOUNDS FOR TREATING CNS DEGENERATIVE DISORDERS
  申请人：Research & Innovation S.p.A.

  公开号：EP1592418B1

  公开（公告）日：2017-09-06